PARP1 and ovarian carcinoma: Based on the molecular mechanisms of actions that target the key points of cancer cells in DNA repair pathways, PARP inhibitors (PARPi) emerge as a new therapeutic approach in the management of EOCs, particularly for HRD (i.e., BRCA 1/2 mutated) ovarian cancers through the mechanism of synthetic lethality [9].